Imagine replacing a cloudy window in a house, but instead of finding a matching old window from another building, you use a high-tech synthetic one that actually fuses with the wall. This device uses a special plastic skirt that tricks the eye's own cells into growing into it, locking it in place permanently. It restores clear vision immediately without needing a human donor.
There is a critical shortage of donor corneas, leaving millions blind, while existing artificial alternatives fail to integrate with the eye and are used only as a last resort.
A synthetic keratoprosthesis (KPro) featuring a biomimetic polymer skirt and a wide aperture acrylic lens, along with a new surgical implantation procedure.
If you are a private clinic dealing with the acute shortage of corneal grafts—where only one cornea is available for every 70 needed—this project developed a synthetic KPro that removes the need for donor tissue. This allows you to treat the 20% of patients who are unsuitable for traditional transplants.
If you are a manufacturer dealing with high failure rates in artificial corneas that fail to integrate with the eye, this project developed a biomimetic skirt technology. This ensures the implant assimilates within the eyewall tissue for a life-long solution.
If you are a health provider dealing with the high cost of repeated grafts, which affect 20%-30% of transplantations in the US and EU, this project developed a procedure that is 50% cheaper than traditional implants.
The CorNeat KPro and its implantation procedure are 50% cheaper than traditional corneal implants.
The CorNeat KPro is described as a patent pending technology.
The project focused on establishing the infrastructure needed for scaled manufacturing and enabling initial sales.
The project executed clinical trials and a usability study required for regulatory approval.
The device is designed as a life-long solution that provides a permanent tissue-integrating result.
The project is led by a single SME, CorNeat Vision Ltd. from Israel, with a 100% industry ratio. This lean structure suggests a fast-track commercialization focus, as the entire EU contribution of EUR 2,422,519 was directed toward a single entity to accelerate clinical trials and manufacturing setup.
Contact CorNeat Vision Ltd. regarding KPro clinical trial results
Contact us to find licensing opportunities for biomimetic tissue-integrating materials.
